Ethiraj Raj, MD
Cardiology · Flint, MINPI 1376532556
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,891 of the $7,902 with a category attached, or 74.5%. It is spread thinly across 31 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2019 at $2,974 and has fallen 98.6% since, to $42 in 2025. Among cardiology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 341 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- Novartis$1K
- Amgen$1K
- Astellas Pharma US Inc$435
- Merck$410
- Johnson & Johnson$406
- plus $3K from 25 others
What the payments were for
- Travel & lodging$1,61420%
- Food & beverage$5,89175%
- Education$3975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 9 | $1,720 |
| Novartis | 67 | $1,218 |
| Amgen | 56 | $1,072 |
| Astellas Pharma US Inc | 7 | $435 |
| Merck | 24 | $410 |
| Johnson & Johnson | 30 | $406 |
| E.r. Squibb & Sons, L.L.C. | 26 | $380 |
| Pfizer | 20 | $328 |
| Boehringer Ingelheim | 14 | $269 |
| Actelion Pharmaceuticals US, Inc. | 8 | $178 |
| Abbott | 6 | $173 |
| Esperion Therapeutics, Inc. | 8 | $141 |
| Medtronic(2 entities) | 12 | $134 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $129 |
| Kestra Medical Technology Services, Inc. | 4 | $121 |
| Alnylam Pharmaceuticals Inc. | 7 | $118 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $115 |
| Boston Scientific | 6 | $115 |
| Regeneron Healthcare Solutions, Inc. | 6 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Teleflex LLC | 3 | $53 |
| Vital Connect, Inc | 1 | $40 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| AstraZeneca | 2 | $33 |
| Bayer | 1 | $24 |
| Sanofi | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Medicomp Inc | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $15 |
| Novo Nordisk | 1 | $13 |
How this compares
$7,902 in reported general payments places this provider in the 95th percentile of 28 cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 301 | $398,843 |
| XareltoRivaroxaban | 118 | $150,165 |
| EntrestoSacubitril/Valsartan | 61 | $65,552 |
| Repatha SureclickEvolocumab | 51 | $63,436 |
| BrilintaTicagrelor | 38 | $29,625 |
| Praluent PenAlirocumab | 18 | $25,741 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 507 | $11,684 |
| Ranolazine ErRanolazine | 61 | $7,402 |
| Atorvastatin Calcium | 246 | $4,916 |
| Metoprolol Succinate | 236 | $4,607 |
| Metoprolol Tartrate | 500 | $4,003 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 21 | $3,625 |
| Carvedilol | 198 | $2,985 |
| Rosuvastatin Calcium | 123 | $2,444 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 74 | $2,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $328 | $398,843301 claims |
| Johnson & JohnsonXarelto | $406 | $150,165118 claims |
| NovartisEntresto | $1,218 | $65,55261 claims |
| AstraZenecaBrilinta | $33 | $29,62538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 cardiology providers in Michigan.
Other cardiology in Flint
- Mohamadali AmlaniFlint$8K
- Sule SalamiDetroit$6K
- Anubhav JainRochester$4K
- Robert GenoveseMidland$0
- Katherine FellBrighton$0
- Daniel EitzmanAnn Arbor$0
- Daniel McAreeAnn Arbor$0
- Ali MahajerinGrand Rapids$0
- James HeinsimerRoyal Oak$0
- David ForstTroy$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.